TERUMO BCT
Manufacturer adverse-event records for TERUMO BCT come from the U.S. Food & Drug Administration (FDA) MAUDE database via openFDA, refreshed March 2026 - see our methodology. Not medical advice.
FDA MAUDE device safety record · 2012–2026 · thin-book · elevated Death-code · balanced
Death-code intensity
TERUMO BCT carries an elevated Death-code share
Death-coded event_type rows are 136 of 6,994 (1.94% · elevated tercile among 434 manufacturers). Absolute volume is thin-book.
What the Death-code reading shows for TERUMO BCT
The standout signal for TERUMO BCT is Death-code intensity: 1.94% of 6,994 reports (elevated tercile), while absolute volume is thin-book.
As a thinner-book manufacturer, a handful of device families can swing the totals; open the device table rather than reading the company headline alone. Event_type counts are not the same population as Patient Outcomes.
Reports span 18 device types, led in this extract by Malfunction at 5,459 (78.1% of event_type total). Peak single-year volume reaches 642 reports across 15 years. These are raw FDA submissions, not adjudicated findings. Snapshot . Verify current communications on the FDA MDR page.
Event Types
Patient Outcomes
FDA patient-outcome codes (separate from event_type). Percentages use this chart's row total.
Devices (18)
Yearly Trend
Read our methodology - how this data is sourced, computed, and verified.